Author pages are created from data sourced from our academic publisher partnerships and public sources.
Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)
The full costs of treating patients with inherited disorders of haemoglobin is extremely variable among countries depending on different health care systems, varying methods of obtaining blood,… Expand
Addiction rare in patients treated with narcotics.
Practical management of iron overload
- J. Porter
- British journal of haematology
- 1 November 2001
The practical management of iron overload requires reliable estimation of body iron content and distribution as well as an understanding of how iron overload translates into clinical consequences. In… Expand
Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.
The rapidity and duration of the response of non-transferrin-bound iron (NTBPI) to chelation therapy are largely unknown and have important implications for the design of optimal chelation regimens.… Expand
Guidelines for the Clinical Management of Thalassaemia
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
Background Following a clinical evaluation of deferasirox (Exjade®) it was concluded that, in addition to baseline body iron burden, ongoing transfusional iron intake should be considered when… Expand
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
- M. D. Cappellini, M. Béjaoui, +19 authors Jean-Francois Baladi
- Clinical therapeutics
- 1 May 2007
BACKGROUND Iron chelation therapy (ICT) with deferoxamine (DFO), the current standard for the treatment of iron overload in patients with transfusion-dependent disorders such as beta-thalassemia,… Expand
Oxidative stress and inflammation in iron‐overloaded patients with β‐thalassaemia or sickle cell disease
Blood transfusion therapy is life‐saving for patients with β‐thalassaemia and sickle cell disease (SCD), but often results in severe iron overload. This pilot study examined whether the biomarkers of… Expand
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
Nontransfusion-dependent thalassemia (NTDT) patients may develop iron overload and its associated complications despite receiving only occasional or no transfusions. The present 1-year, randomized,… Expand
"Hearing the Voices of the Poor": Assigning Poverty Lines on the Basis of Local Perceptions of Poverty. A Quantitative Analysis of Qualitative Data from Participatory Wealth Ranking in Rural South…
Summary. — We applied a mixed-methods approach to participatory wealth ranking (PWR) to identify the number of poor households in eight villages of rural South Africa and describe how poor they are.… Expand